Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agile Therapeutics (AGRX)
OTHER OTC:AGRX
Holding AGRX?
Track your performance easily
AGRX Stock Chart & Stats
Day’s Range$1.51 - $1.52
52-Week Range― - ―
Previous Close$1.51
Volume120.94K
Average Volume (3M)N/A
Market Cap
$10.43M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Agile Therapeutics News
PremiumCompany Announcements
Agile Therapeutics Embarks on New Chapter Post-Merger
PremiumCompany Announcements
Agile Therapeutics Merges with Insud Pharma Subsidiary
PremiumCompany Announcements
Agile Therapeutics Releases Updated Investor Presentation
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGRX FAQ
What was Agile Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Agile Therapeutics’s market cap?
Currently, no data Available
When is Agile Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Agile Therapeutics’s earnings last quarter?
Currently, no data Available
Is Agile Therapeutics overvalued?
According to Wall Street analysts Agile Therapeutics’s price is currently Overvalued.
Does Agile Therapeutics pay dividends?
Agile Therapeutics does not currently pay dividends.
What is Agile Therapeutics’s EPS estimate?
Agile Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Agile Therapeutics have?
Currently, no data Available
What happened to Agile Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Agile Therapeutics?
Among the largest hedge funds holding Agile Therapeutics’s share is Perceptive Advisors LLC. It holds Agile Therapeutics’s shares valued at N/A.
---
Agile Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 10.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.03%
Trailing 12-Months
Company Description
Agile Therapeutics
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
---
AGRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---